| Christopher Pohlman, MD | |
|
2750 Broadway St, Boulder, CO 80304-3573 | |
| (303) 440-3000 | |
| Not Available |
| Full Name | Christopher Pohlman |
|---|---|
| Gender | Male |
| Speciality | General Surgery |
| Experience | 25 Years |
| Location | 2750 Broadway St, Boulder, Colorado |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1063496669 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208600000X | Surgery | 43809 (Colorado) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Boulder Community Health | Boulder, CO | Hospital |
| Centura Health-avista Adventist Hospital | Louisville, CO | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Boulder Medical Center, Pc | 4183536204 | 79 |
News Archive
Preliminary results of a Phase II single-arm study to be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting showed that Eisai's lenvatinib demonstrated an Objective Response Rate of 59% (34/58, 95% CI: 45-71), based on an updated investigator assessment, in patients with advanced radioiodine (RAI)-refractory differentiated thyroid cancer.
CLC bio, the world's leading bioinformatics solution provider, today announced a partnership with Ion Torrent, a new sequencing company started by Dr. Jonathan Rothberg, the founder of 454 Life Sciences. The partnership will ensure that data can directly flow off of the Ion Personal Genome Machine sequencer and into CLC bio's solutions, like CLC Genomics Workbench or CLC Genomics Server.
The Bobby Moore Fund for Cancer Research UK is offering up to 40 participants a travel experience with a difference to the beautiful Republic of South Africa, just months before the country hosts the World Cup.
Massachusetts General Hospital (MGH) investigators have shown that an MGH-developed, microchip-based device that detects and analyzes tumor cells in the bloodstream can be used to determine the genetic signature of lung tumors, allowing identification of those appropriate for targeted treatment and monitoring genetic changes that occur during therapy. A pilot study of the device called the CTC-chip will appear in the July 24 New England Journal of Medicine and is receiving early online release.
Researchers from Brown University and Harvard Medical School are calling for improved decision-making in the use of feeding tubes for hospitalized nursing home residents with advanced dementia.
› Verified 4 days ago
| Entity Name | Boulder Medical Center, Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1306820923 PECOS PAC ID: 4183536204 Enrollment ID: O20031105000512 |
News Archive
Preliminary results of a Phase II single-arm study to be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting showed that Eisai's lenvatinib demonstrated an Objective Response Rate of 59% (34/58, 95% CI: 45-71), based on an updated investigator assessment, in patients with advanced radioiodine (RAI)-refractory differentiated thyroid cancer.
CLC bio, the world's leading bioinformatics solution provider, today announced a partnership with Ion Torrent, a new sequencing company started by Dr. Jonathan Rothberg, the founder of 454 Life Sciences. The partnership will ensure that data can directly flow off of the Ion Personal Genome Machine sequencer and into CLC bio's solutions, like CLC Genomics Workbench or CLC Genomics Server.
The Bobby Moore Fund for Cancer Research UK is offering up to 40 participants a travel experience with a difference to the beautiful Republic of South Africa, just months before the country hosts the World Cup.
Massachusetts General Hospital (MGH) investigators have shown that an MGH-developed, microchip-based device that detects and analyzes tumor cells in the bloodstream can be used to determine the genetic signature of lung tumors, allowing identification of those appropriate for targeted treatment and monitoring genetic changes that occur during therapy. A pilot study of the device called the CTC-chip will appear in the July 24 New England Journal of Medicine and is receiving early online release.
Researchers from Brown University and Harvard Medical School are calling for improved decision-making in the use of feeding tubes for hospitalized nursing home residents with advanced dementia.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Christopher Pohlman, MD 2750 Broadway St, Boulder, CO 80304-3573 Ph: (303) 440-3000 | Christopher Pohlman, MD 2750 Broadway St, Boulder, CO 80304-3573 Ph: (303) 440-3000 |
News Archive
Preliminary results of a Phase II single-arm study to be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting showed that Eisai's lenvatinib demonstrated an Objective Response Rate of 59% (34/58, 95% CI: 45-71), based on an updated investigator assessment, in patients with advanced radioiodine (RAI)-refractory differentiated thyroid cancer.
CLC bio, the world's leading bioinformatics solution provider, today announced a partnership with Ion Torrent, a new sequencing company started by Dr. Jonathan Rothberg, the founder of 454 Life Sciences. The partnership will ensure that data can directly flow off of the Ion Personal Genome Machine sequencer and into CLC bio's solutions, like CLC Genomics Workbench or CLC Genomics Server.
The Bobby Moore Fund for Cancer Research UK is offering up to 40 participants a travel experience with a difference to the beautiful Republic of South Africa, just months before the country hosts the World Cup.
Massachusetts General Hospital (MGH) investigators have shown that an MGH-developed, microchip-based device that detects and analyzes tumor cells in the bloodstream can be used to determine the genetic signature of lung tumors, allowing identification of those appropriate for targeted treatment and monitoring genetic changes that occur during therapy. A pilot study of the device called the CTC-chip will appear in the July 24 New England Journal of Medicine and is receiving early online release.
Researchers from Brown University and Harvard Medical School are calling for improved decision-making in the use of feeding tubes for hospitalized nursing home residents with advanced dementia.
› Verified 4 days ago
Kilsan Koh, M.D. Surgery Medicare: Medicare Enrolled Practice Location: 1000 Alpine Ave, Suite 210, Boulder, CO 80304 Phone: 303-443-1008 Fax: 303-417-1111 | |
Dr. Laura A Harmon, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 4743 Arapahoe Ave Ste 100, Boulder, CO 80303 Phone: 303-443-2123 Fax: 303-443-9497 | |
Dr. Charles Graham Jones, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 4743 Arapahoe Ave, Suite 100, Boulder, CO 80303 Phone: 303-443-2123 Fax: 303-443-9497 | |
Dr. Matthew John Gawart, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 4743 Arapahoe Avenue, Suite 102, Boulder, CO 80303 Phone: 303-449-3642 | |
Dr. Richard Jay Fox, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 4743 Arapahoe Ave, #102, Boulder, CO 80303 Phone: 303-449-3642 Fax: 303-440-7298 | |
Kyle Jordan Marthaller, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 4743 Arapahoe Ave, Suite 100, Boulder, CO 80303 Phone: 303-443-2123 Fax: 303-443-9497 |